Bilal Khokhar1, Linda Simoni-Wastila2, Julia F Slejko2, Eleanor Perfetto2,3, Min Zhan2, Gordon S Smith2,4. 1. General Dynamics Health Solutions, Defense and Veterans Brain Injury Center, Silver Spring, MD, USA. 2. University of Maryland, Baltimore, MD, USA. 3. National Health Council, Washington, DC, USA. 4. West Virginia University, Morgantown, WV, USA.
Abstract
BACKGROUND: Traumatic brain injury (TBI) is a significant public health concern for older adults. Small-scale human studies have suggested pre-TBI statin use is associated with decreased in-hospital mortality following TBI, highlighting the need for large-scale translational research. OBJECTIVE: To investigate the relationship between pre-TBI statin use and in-hospital mortality following TBI. METHODS: A retrospective study of Medicare beneficiaries 65 and older hospitalized with a TBI during 2006 to 2010 was conducted to assess the impact of pre-TBI statin use on in-hospital mortality following TBI. Exposure of interest included atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Beneficiaries were classified as current, recent, past, and nonusers of statins prior to TBI. The outcome of interest was in-hospital mortality. Logistic regression was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) comparing current, recent, and prior statin use to nonuse. RESULTS: Most statin users were classified as current users (90%). Current atorvastatin (OR = 0.88; 95% = CI 0.82, 0.96), simvastatin (OR = 0.84; 95% CI = 0.79, 0.91), and rosuvastatin (OR = 0.79; 95% CI = 0.67, 0.94) use were associated with a significant decrease in the risk of in-hospital mortality following TBI. CONCLUSIONS: In addition to being the most used statins, current use of atorvastatin, rosuvastatin, and simvastatin was associated with a significant decrease in in-hospital mortality following TBI among older adults. Future research must include clinical trials to help exclude the possibility of a healthy user effect in order to better understand the impact of statin use on in-hospital mortality following TBI.
BACKGROUND: Traumatic brain injury (TBI) is a significant public health concern for older adults. Small-scale human studies have suggested pre-TBI statin use is associated with decreased in-hospital mortality following TBI, highlighting the need for large-scale translational research. OBJECTIVE: To investigate the relationship between pre-TBI statin use and in-hospital mortality following TBI. METHODS: A retrospective study of Medicare beneficiaries 65 and older hospitalized with a TBI during 2006 to 2010 was conducted to assess the impact of pre-TBI statin use on in-hospital mortality following TBI. Exposure of interest included atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Beneficiaries were classified as current, recent, past, and nonusers of statins prior to TBI. The outcome of interest was in-hospital mortality. Logistic regression was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) comparing current, recent, and prior statin use to nonuse. RESULTS: Most statin users were classified as current users (90%). Current atorvastatin (OR = 0.88; 95% = CI 0.82, 0.96), simvastatin (OR = 0.84; 95% CI = 0.79, 0.91), and rosuvastatin (OR = 0.79; 95% CI = 0.67, 0.94) use were associated with a significant decrease in the risk of in-hospital mortality following TBI. CONCLUSIONS: In addition to being the most used statins, current use of atorvastatin, rosuvastatin, and simvastatin was associated with a significant decrease in in-hospital mortality following TBI among older adults. Future research must include clinical trials to help exclude the possibility of a healthy user effect in order to better understand the impact of statin use on in-hospital mortality following TBI.
Entities:
Keywords:
cardiovascular drugs; geriatrics; pharmacoepidemiology; trauma; trauma medicine
Authors: Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer Journal: J Neurotrauma Date: 2014-01-15 Impact factor: 5.269
Authors: Nienke van Rein; Suzanne C Cannegieter; Saskia le Cessie; Frits R Rosendaal; Pieter H Reitsma; Felix J M van der Meer; Willem M Lijfering Journal: Am J Epidemiol Date: 2016-04-18 Impact factor: 4.897
Authors: Jeffrey P Cuthbert; Cynthia Harrison-Felix; John D Corrigan; Scott Kreider; Jeneita M Bell; Victor G Coronado; Gale G Whiteneck Journal: J Head Trauma Rehabil Date: 2015 Mar-Apr Impact factor: 2.710
Authors: Teodor T Postolache; Abhishek Wadhawan; Adem Can; Christopher A Lowry; Margaret Woodbury; Hina Makkar; Andrew J Hoisington; Alison J Scott; Eileen Potocki; Michael E Benros; John W Stiller Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472